INTRODUCTION
Interleukin-9 (IL-9)-producing CD4 + T helper type 9 (T H 9) cells have been proposed as a newly described proinflammatory subset of T H cells. In mouse models, T H 9 cells enhanced immune responses to melanoma and helminth infection and contributed to pathogenicity in autoimmune and allergic animal models of colitis, uveitis, experimental autoimmune encephalomyelitis (EAE), and asthma (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . In humans, IL-9 production was increased in the asthmatic lung and in T cells from infants with atopic dermatitis (12) (13) (14) (15) (16) . Aside from these reports, studies of human T H 9 cells have focused almost exclusively on naïve or memory T cells driven to produce IL-9 in vitro by stimulation with exogenous transforming growth factor-b (TGF-b) (6, 7, 14, 17) .
Several unanswered questions remain regarding the biology of T H 9 cells. First, the prevalence, characteristics, and function of T H 9 cells arising in vivo in humans remain unstudied. Second, T H 2, T H 17, and regulatory T (T reg ) cells can produce IL-9 after specific in vitro manipulations, raising the question as to whether IL-9-producing T H 9 cells exist as a discrete T cell subset (6, 17) . Third, innate lymphoid cells (ILCs) were the major source of IL-9 in one mouse model, and the relative importance of ILCs versus T cell-derived IL-9 has not been established (3) . Last, IL-9 production was no longer demonstrable at sites of established tissue inflammation in several animal models, despite the requirement of IL-9 for initial development of the inflammatory state (18, 19) . The eventual fate of IL-9-producing T cells in these models remains undetermined.
We report here studies of IL-9-producing T cells isolated from human blood and peripheral tissues. We find that human T H 9 cells are a discrete, identifiable T cell subset, largely tropic for the skin, that have the capacity to amplify immune responses by enhancing cytokine production from T H 1, T H 2, T H 9, and T H 17 cells.
RESULTS

IL-9 is transiently and selectively produced by skin-tropic T H cells after stimulation with Candida albicans
On the basis of evidence that epithelial barrier tissues are progressively colonized by memory T cells responding to pathogens encountered through that tissue (20, 21) , we studied human tissue-tropic T cells from peripheral blood for their capacity to make IL-9. Skin-and guttropic memory T H cells were isolated based on expression of the skin-homing receptor cutaneous lymphocyte antigen (CLA) or the guthoming integrin a 4 b 7 . To most closely mimic pathophysiologic stimulation, we stimulated T cells with autologous monocytes pulsed with a panel of viral, bacterial, and fungal pathogens and analyzed subsequent proliferation and cytokine production. We observed enhanced proliferation of tissue-tropic T cells after stimulation with pathogens commonly encountered through that respective epithelial surface (Fig. 1A  and fig. S1 ). CLA + skin-tropic T cells proliferated more than other populations when stimulated with the skin organism Staphylococcus epidermidis, a 4 b 7 + gut-tropic T cells preferentially proliferated to the gut pathogens rotavirus and Salmonella typhimurium, and the nongut-tropic/non-skin-tropic T cells (which include lung-homing T cells) proliferated maximally to the lung pathogens influenza A and Mycoplasma pneumoniae. T cell responses to herpes simplex virus-1 (HSV-1) and Candida albicans were maximal in skin-tropic T cells but also present in other tissue-homing populations.
We next evaluated cytokine production in response to pathogen exposure. Surprisingly, we found substantial IL-9 production only in cultures of skin-tropic CLA + T cells stimulated with C. albicans-pulsed monocytes (Fig. 1B) ; in contrast, other T H cell cytokines [for example, interferon-g (IFN-g) (T H 1), IL-13 (T H 2), and IL-17 (T H 17)] were detected at variable levels in all tissue-homing subsets and with all pathogens tested (Fig. 1, C to E) . IFN-g suppresses IL-9 production in mouse T cells, and pathogen-induced production of IFN-g could be masking IL-9 production (22) . To evaluate this possibility, we tested pathogen responses in the presence of IFN-g-neutralizing antibody. IFN-g blockade significantly increased IL-9 production in response to C. albicans but did not affect IL-9 production in response to other pathogens ( fig. S2A ). The lack of IL-9 production in C. albicansstimulated a 4 b 7 + and CLA − /a 4 b 7 − T H cells was not a consequence of differential stimulation; T H cell proliferation was observed in all T H cell subsets, although it was highest in CLA + T cells (Fig. 1F) . We further studied the source and expression kinetics of IL-9 produced in response to C. albicans by stimulating peripheral blood mononuclear cells (PBMCs) with C. albicans or S. aureus, organisms known to induce strong T H 17 responses (23) (Fig. 1G) . Both organisms induced equivalent IL-17 production. However, IL-9 was only induced by C. albicans, and IL-9 production was unique in that it was transient, peaked at day 6, and declined rapidly thereafter (Fig. 1H ). These results demonstrate that transient IL-9 expression is specifically induced in skin-homing CLA + T H cells by C. albicans.
Human T H 9 cells are a distinct T cell population tropic for the skin Our previous experiments, using pathogens to stimulate the cytokine production of circulating peripheral blood effector T cells, found IL-9-producing T cells only within the skin-homing T H population. To determine whether T H 9 cells specific for other tissues existed but were not specific for the pathogens we tested, we isolated CLA + , a 4 b 7 + , and CLA − /a 4 b 7 − CD25 − effector T H cells from the blood and polyclonally stimulated these T cells with anti-CD3/anti-CD2/anti-CD28. We analyzed cytokine production by intracellular cytokine staining (Fig. 2, A and B) and multiplex bead analysis (Fig. 2C) . IL-9 production was enriched in skin-tropic CLA + T H cells, although some production was also observed in the gut-tropic and non-skin-tropic/non-gut-tropic CLA − /a 4 b 7 − T cells, a population that included lung-homing T cells. The kinetics of IL-9 production were unique in that it was produced only transiently after activation. Multiplex bead analysis of T cell supernatants confirmed that most IL-9 was produced by CLA + skin-homing T cells (Fig. 2C) . At the time of peak IL-9 production (day 2), simultaneous staining for all four cytokines demonstrated that most IL-9 + skinhoming T H cells lacked coexpression of other T H lineage cytokines (IFN-g, IL-17, and IL-13), consistent with their identity as a distinct T cell subset (Fig. 2, D and E) . In the smaller populations of IL-9-producing T cells that did coproduce IFN-g, IL-13, or IL-17, IL-9 − memory CD4 + T cells were isolated from PBMCs of healthy donors and separately stimulated with autologous monocytes pulsed with a panel of viral, bacterial, and fungal antigen preparations. Proliferation was assayed by carboxyfluorescein diacetate succinimidyl ester (CFSE) dilution, and maximal proliferation for each antigen was used to calculate relative responses of other T cell subsets (mean + SEM of duplicates). *P = 0.0001. (B to E) IL-9 was produced selectively by skin-tropic T cells in response to C. albicans. Cytokine production of T cell subsets after stimulation with autologous antigen-pulsed monocytes was measured in cell culture supernatants using a bead-based multiplex assay (mean + SEM of duplicates).
Significant IL-9 production was observed only in CLA + skin-tropic T cells stimulated with C. albicans, whereas IFN-g, IL-13, and IL-17 were produced in variable amounts by all tissue-tropic subsets and in response to all antigens tested. (F) All tissue-tropic T cell subsets proliferated in response to C. albicans, demonstrating that selective IL-9 production by skin-tropic T cells was not the result of poor recognition of C. albicans by other T cell subsets. The percent CFSE low T cells is shown (mean + SEM of duplicates). (G and H) IL-9 is transiently produced after pathogen stimulation. T cells were stimulated with C. albicans and S. aureus, and IL-9 and IL-17 production was assessed at different time points by flow cytometry after stimulation with phorbol 12-myristate 13-acetate and ionomycin. Cytokine production of stimulated T H cells on day 6 (G) and the kinetics of IL-9 and IL-17 production (H) are shown (mean + SD). Data are representative of independent experiments with five (A and F), three (B to E), or two (G and H) donors.
was also transiently produced ( fig. S4 ). In contrast to CLA + cells and in accordance with previous reports, a 4 b 7 + T H cells highly expressed IFN-g (24) , and CLA − /a 4 b 7 − T H cells were enriched for IL-17-producing T cells (25) (Fig. 2B) . The production of IL-9 by CLA + T H cells was not affected by including anti-TGF-b-neutralizing antibody, ruling out potential autocrine induction of IL-9 by endogenous TGF-b (Fig. 2F ). These results demonstrate that IL-9 is selectively and transiently produced by a distinct population of T H 9 cells expressing cutaneous homing receptors, which suggests that these cells are tropic for the skin.
T H 9 cells are selectively found in human skin and are independent of TGF-b and IL-2 Memory T cells are frequent in human peripheral tissues; there are about 20 billion antigen-experienced memory T cells in the skin of a healthy adult, twice the number of total circulating T cells (26) . Analogous populations of memory T cells have been found in human lung and gut (27, 28) . Studies in mice have shown that pathogen-specific T cells accumulate in epithelial barrier tissues such as the skin after infection and are protective against pathogen reexposure, even in the absence of circulating T cells (21, (29) (30) (31) (32) . In both mice and humans, a subpopulation of these resident memory T (T RM ) cells are sessile and nonrecirculating (20, 21, 31) . It is therefore critical to study the T cells resident within peripheral tissues to gain a true understanding of effector memory T cell function. We isolated tissue T RM cells from healthy human skin, small intestine, and lung. T H cells transiently producing IL-9 after activation were found exclusively in skin and were largely absent from gut or lung (Fig. 3A) . Similar findings were observed in T cells isolated from skin by collagenase digestion ( − CD25 − memory CD4 + T cells (T EFF ) were isolated from healthy donors and polyclonally stimulated with aCD3/aCD2/aCD28. The production of IL-9, IFN-g, IL-13, and IL-17 was assessed by flow cytometry after stimulation with PMA and ionomycin at the indicated time points. Histograms from an individual donor (A) and aggregate data are shown (B) (mean + SD). Most IL-9 production was observed in CLA + skin-tropic T cells, and IL-9 was produced only transiently after activation, in contrast to other cytokines tested simultaneously (IL-13, IL-17, and IFN-g). (C) Cytokine production as measured by bead multiplex analysis of supernatants from tissue-tropic subsets on day 4 after stimulation (mean + SD); results confirmed flow cytometry studies, demonstrating that most IL-9 is produced by CLA + T cells. (D and E) Most IL-9-producing T cells lacked production of other T H lineage cytokines. Two days after stimulation, CLA + T EFF cells were analyzed by flow cytometry for coproduction of IL-9 and IL-17, and IFN-g and IL-13. Representative histograms (D) and aggregate data (E) are shown (mean + SD). (F) IL-9 production was not dependent on the presence of TGF-b. IL-9 in supernatants from T cells stimulated for 4 days in the presence of neutralizing antibody to TGF-b or an isotype-matched control antibody is shown (mean + SD). Data are representative of independent experiments with at least four donors.
anti-IL-2 antibodies to cultures did not alter IL-9 production ( Fig. 3B and fig. S2C ), demonstrating that skin-resident T H 9 cells were not dependent on TGF-b or IL-2 for survival or cytokine production.
In mice, it has been suggested that ILCs, not T cells, are the main source of IL-9 produced in vivo (3). IL-33 and IL-2 can induce production of IL-9 from human ILCs (33) . We observed no IL-9 production after treatment of healthy skin cells with IL-33 and IL-2, but CD3 + T cells were a major source of IL-9, both before and after polyclonal T cell stimulation (Fig. 3, C S4 ). IL-9 + skin-resident T H cells also lacked coexpression of IL-10, IL-22, and the T reg marker FoxP3 but coexpressed tumor necrosis factor-a (TNF-a) and the cytotoxic molecule granzyme B (Fig. 3F) , further supporting the notion that T H 9 cells are a distinct subset with proinflammatory and cytotoxic properties (4).
Human T H 9 cells have autocrine and paracrine activities
In T H 9 cells isolated from human blood and skin, we observed that peak IL-9 production preceded maximal activationinduced up-regulation of IFN-g, IL-17, and IL-13 in T H cells (Fig. 4, A and B) . We next investigated if IL-9 could induce or enhance production of other effector cytokines in skin-tropic T H cells. Blocking IL-9 with neutralizing antibody at the initiation of in vitro culture strongly inhibited subsequent up-regulation of IL-9, IFN-g, IL-13, and IL-17 in CLA + T H cells (Fig. 4C ). IL-9-neutralizing antibody also reduced T cell proliferation at early (day 4), but not late, time points (Fig. 4E ) and had no significant effects on cell viability ( fig. S2D ). In parallel, we found that IL-9 receptor (IL-9R) expression was highly enriched in activated CLA + T H cells and increased after activation (Fig. 4D) . + T cells are the major source of IL-9 in human skin. Cell suspensions from human skin were simulated with PMA and ionomycin before or after 12 hours of stimulation with aCD3/aCD2/aCD28 beads. CD3 + T cells were the major source of IL-9 both before and after T cell stimulation. (D and E) ILCs were not an appreciable source of IL-9 in healthy human skin. Cell suspensions from human skin were stimulated for 4 days (4d) with either (D) IL-2 (10 U/ml) + IL-33 (50 ng/ml) (to stimulate ILCs) or (E) aCD3/aCD2/aCD28 beads (to stimulate T cells) and then treated with PMA and ionomycin. IL-9 was not produced by CD3
− cells after IL-2 + IL-33 but was produced by CD3 + cells after bead treatment. CD3 + T cells produced IFN-g without bead stimulation, but IL-9 production was not observed unless T cells were first bead-stimulated. Human T H 9 cells are increased in psoriatic skin lesions Given the ability of T H 9 cells to enhance the production of proinflammatory cytokines by other T cells, we carried out immunohistochemical studies on the skin lesions of T H 1/T H 17-mediated (psoriasis) and T H 2-mediated (atopic dermatitis) human skin diseases. IL-9-producing T cells were evident within the skin lesions of both diseases (Fig. 5) . The number of IL-9-producing cells was significantly higher in psoriatic skin lesions compared to healthy skin (Fig. 5B) . Although atopic dermatitis skin lesions also tended to have increased numbers of IL-9-producing cells, this increase was not statistically significant. To establish that IL-9 in psoriatic skin lesions was produced by T cells, we performed double-color immunofluorescence staining of psoriatic skin lesions. A population of IL-9-producing cells expressing CD3 and CD4, but not CD8, was identified (Fig. 6, A to C) . A proportion of IL-9-producing T cells were observed to be in the process of cell division (Fig. 6, D and E), consistent with our in vitro observation that IL-9 is produced transiently and only by activated cells. A subset of CD3 − IL-9-producing cells were also demonstrable in psoriatic skin lesions, suggesting the possibility that ILCs or other IL-9-producing cell types may contribute to IL-9 production (Fig. 6F) .
DISCUSSION
We report here a comprehensive characterization of human IL-9-producing T cells. We found that IL-9 was primarily produced by a discrete and stable population of T cells, strongly suggesting that T H 9 cells do indeed exist in humans. Unlike human and mouse T cells generated by differentiation from naïve cells in vitro, human T H 9 cells isolated from human blood and tissues lacked production of other T H lineage cytokines, coproduced TNF-a and granzyme B, lacked FoxP3 expression, and were not dependent on the presence of TGF-b or exogenous IL-2. Both the naturally occurring, in vivo-differentiated T H 9 cells studied in this report and T H 9 cells generated by in vitro differentiation (7, 17) lack IL-10 production, a feature that distinguishes them from mouse T H 9 cells.
Human T H 9 cells had unique features that distinguished them from other T H lineages. In healthy adults, T H 9 cells were found primarily among the CLA + skin-homing effector T cell population and were present in healthy human skin, but were effectively absent from human small intestine and lung. A demonstrable proportion of CLA + T H 9 cells were specific for C. albicans, suggesting that under normal conditions, T H 9 cells may play a role in protecting against certain extracellular pathogens. In contrast to the production of other inflammatory cytokines, production of IL-9 by T H 9 cells was transient, peaking at day 2 after stimulation in circulating T H 9 cells and at day 4 after stimulation in skin-resident T H 9 cells. Transient production of IL-9 with subsequent down-regulation is a pattern that has also been observed in mouse in vitro-differentiated T H 9 cells (34). The transient nature of IL-9 production may explain why in mouse models of T H 9-mediated inflammation, IL-9-producing T cells are often not readily demonstrable at the affected sites (18, 19) . What becomes of T H 9 cells after they stop producing IL-9 is not clear; possibilities include cessation of cytokine production, apoptopic cell death, or differentiation into other T H cell subsets.
In both circulating and skin-resident T H 9 cells, maximal IL-9 production preceded the activation-induced up-regulation of other T H inflammatory cytokines including IFN-g, IL-17, and IL-13. We found that IL-9R expression was highly enriched in activated CLA + T H cells, suggesting that skin-homing T H cells may be both a source and a target of IL-9. Indeed, blocking IL-9 in vitro strongly inhibited the upregulation of not only IL-9 but also IFN-g, IL-13, and IL-17 in CLA +
Fig. 4. Human T H 9 cells have autocrine and paracrine proinflammatory activity. (A and B)
IL-9 production is transient and precedes the up-regulation of other inflammatory cytokines. T cells isolated from blood (A) and skin (B) were stimulated with aCD3/aCD2/aCD28, and production of IL-9, IFN-g, IL-17, and IL-13 was assessed at the indicated time points by flow cytometry after stimulation with PMA and ionomycin. (C) IL-9 production is required for maximal production of IL-9 itself as well for as the production of other inflammatory cytokines. CLA + T EFF cells were stimulated for 2 days with aCD3/aCD2/aCD28 in the presence of neutralizing antibody to IL-9 or isotype-matched control antibody. T H cells and reduced early T cell proliferation. It has been proposed previously that IL-9 functions indirectly via the induction of IL-13 and IL-5, and therefore, IL-9 has a regulatory role on cells that produce T H 2 cytokines (3). Our results, however, indicate that human IL-9 induces the production of cytokines from multiple T cell subsets, at least in skin-homing T cells. Our results suggest that T H 9 cell activation in tissues could initiate inflammation via TNF-a production and via their autocrine and paracrine activity, leading to enhanced activation and cytokine production by T H 1, T H 2, T H 9, and T H 17 cells. Such a role for T H 9 cells in the initiation of inflammation is consistent with findings in mouse models where dermal injection of IL-9 enhanced T H 17-related psoriasiform inflammation in K5.hTGF-b1 transgenic mice (35) , blockade of IL-9 suppressed both production of IL-17 by autoreactive T cells and their ability to initiate disease in adoptive transfer EAE (36) , and T H 9 cells were found to be critical for the recruitment and activation of IFN-g-producing anti-melanomaspecific T cells (5) . Consistent with a possible role in initiating and enhancing skin inflammation, we found that IL-9-producing T H 9 cells were significantly increased in the skin lesions of psoriasis.
Limitations of this study include an inability to track human T H 9 cells, as is possible in transgenic mice, to determine the eventual fate of IL-9-producing T cells. Also, the presence of IL-9-producing T H 9 cells in human psoriatic skin lesions, their ability to amplify T cell responses, and a role for IL-9 in one mouse model of psoriasiform dermatitis are intriguing, but our results do not constitute proof that T H 9 cells play a causative pathogenic role in human psoriasis. Last, the panel of bacterial and viral antigens we used to examine T cell reactivity was diverse but not comprehensive, and it is likely that T H 9 cells reactive to multiple other pathogens also exist in vivo in humans.
In summary, we find that memory T H 9 cells can be readily isolated from human blood and tissue, are preferentially skin-tropic or skin-resident, and are present in both healthy and diseased human skin. T H 9 cells isolated from humans were a discrete T cell subset that showed no dependence on the presence of TGF-b, lacked IL-10 production but coproduced TNF-a and granzyme B, and were essential for maximal inflammatory cytokine production of CLA + T H 1, T H 2, T H 9, and T H 17 cells. The specificity of many memory T H 9 cells for C. albicans suggests that, in addition to antitumor effects, T H 9 cells may play a critical role in healthy individuals in the defense against extracellular − IL-9-producing cells was also present in psoriatic skin lesions. Scale bars, 10 mm. DAPI, 4′,6-diamidino-2-phenylindole.
pathogens. The ability of T H 9 cells to enhance proliferation and the production of inflammatory cytokines from other T cell subsets and their increased presence in psoriasis skin lesions suggest that T H 9 cells may also participate in initiating and maintaining cutaneous inflammation.
MATERIALS AND METHODS
Study design/experimental design This is an experimental laboratory study performed on human tissue samples. All studies were performed in accordance with the Declaration of Helsinki. Blood from healthy individuals was obtained after leukapheresis, skin was obtained from healthy patients undergoing cosmetic surgery procedures, and lung and intestinal specimens were obtained as discarded tissues after resection of small tumors distant from the provided specimens; all tissues were collected with previous approval from the Partners Institutional Review Board. Skin samples for immunohistochemistry and immunofluorescence studies were obtained from patients seen at the Department of Dermatology, Inselspital/University of Bern, Bern, Switzerland. The study on human patient samples was approved by the Medical Ethics Committee of the Canton of Bern, Switzerland (approval 35/08). Written informed consent was obtained from all patients. Enumeration of IL-9-producing cells in immunofluorescence and immunohistochemical studies was done in an investigator-blinded fashion. Mechanistic studies on cells derived from blood and human tissues were performed with in vitro assays without blinding or randomization. Study components were not predefined.
Antibodies and flow cytometry
All antibodies used in this study are listed in table S1. For analysis of cytokine production, T cells were stimulated with either control medium or PMA (50 ng/ml) and ionomycin (750 ng/ml) plus brefeldin A (10 mg/ml) (Calbiochem) for 4 hours. Cells were then surface-stained, fixed, permeabilized, stained with anti-cytokine antibodies, and examined by flow cytometry. Analysis of flow cytometry samples was performed on Becton Dickinson FACSCanto instruments, and data were analyzed with FACSDiva software (V5.1). To set gates, cells were stained with isotype control antibodies and gates were set such that <1% of cells were present in all three positive staining quadrants.
Culture medium
Cell culture medium consisted of X-VIVO 15 (Lonza) supplemented with 2% (v/v) human serum type AB (Sigma). Where indicated, recombinant human IL-2 was added at 50 IU/ml.
Cell sorting
PBMCs from healthy donors were isolated with Histopaque-1077 (Sigma). CD14 + monocytes were isolated by positive selection with magnetic microbeads (Miltenyi). Total CD4 + memory T cells were isolated by negative selection with the memory CD4 + T Cell Isolation kit (Miltenyi) and stained for FACS with anti-a 4 b 7 , followed by anti-mouse immunoglobulin G (IgG), then with anti-CLA and anti-CD25. − memory T cell subsets were sorted on a FACSAria (BD Biosciences). Sorting purity of T cell subsets was typically more than 95% in post-sort analysis, with the exception of the CLA − subset, where a purity of >85% was achieved.
T cell stimulation with pathogen-pulsed monocytes Commercially available antigen preparations from HSV-1, rotavirus, influenza A (H3N2), and M. pneumoniae were obtained from Microbix. Antigen preparations from S. epidermidis, S. typhimurium, Staphylococcus aureus, and C. albicans were generated by heat-killing microbes at 65°C for 1 hour (all four pathogens), followed by three freeze-thaw cycles (bacteria only). Pathogen concentrations were determined by optical density measurements (Bio-Rad) according to the manufacturer's instructions. All antigen preparations were used at the concentration that resulted in maximal proliferation in titration experiments using CFSE dilution. Monocytes (2.5 × 10 4 ) were preincubated with antigen preparations for 6 hours at 37°C. CFSE-labeled purified CD4 + memory T cell subsets (5 × 10 4 ) were then cocultured with the antigenpulsed autologous monocytes for 7 days before analysis of CFSE dilution on a FACSCanto (BD Biosciences). CFSE labeling was performed according to standard protocols. On day 5 of coculture, supernatants were saved and cytokine concentrations were measured with a custom-made Luminex bead assay, as previously described (37) . For analysis of pathogeninduced IL-9 expression kinetics, PBMCs (4 × 10 5 ) were cultured with C. albicans or S. aureus and analyzed for the expression of IL-9 and IL-17 at different time points by intracellular FACS staining after stimulation for 5 hours with PMA and ionomycin. For experiments measuring IL-9 production in the presence or absence of IFN-g blockade ( fig. S2A ), CFSE-labeled PBMCs (2 × 10 5 ) were cultured in the presence of anti-IFN-g (10 mg/ml) or mouse IgG (10 mg/ml). On day 5 of culture, supernatants were harvested and IL-9 concentrations were measured with an IL-9 ELISA kit (ELISA MAX, BioLegend) according to the manufacturer's instructions.
Polyclonal activation of T EFF and cytokine expression kinetics FACS-sorted T EFF subsets (2 × 10 4 ) were polyclonally activated using beads coated with antibodies against CD3, CD2, and CD28 (T cell/bead = 2:1, Miltenyi). Before activation and at different time points thereafter, T cells were additionally stimulated for 5 hours with PMA and ionomycin in the presence of brefeldin A and then intracellularly stained for IL-9, IFN-g, IL-13, and IL-17 for FACS analysis according to standard protocols. Supernatants were collected at day 4 after polyclonal stimulation, and cytokines were measured as described above. Where indicated, the following neutralizing antibodies were added at the start of the culture (all at 10 mg/ml): anti-TGF-b (clone 1D11, R&D Systems), anti-IL-9 (MH9D1, BioLegend), IgG1 control antibody (MG1-45, BioLegend), anti-IL-2 (4 mg/ml, polyclonal goat IgG; R&D Systems), or polyclonal goat IgG (4 mg/ml, R&D Systems).
Quantitative real-time PCR for IL-9R Total RNA was isolated from FACS-sorted T cell subsets 2 days after polyclonal activation (as described above) with the RNeasy Plus Mini Kit (Qiagen) according to the manufacturer's instructions. Complementary DNA was generated with the SuperScript VILO cDNA Synthesis kit (Life Technologies), and quantitative real-time PCR was performed with the ABI StepOnePlus Instrument and the Fast SYBR Green Master Mix (Applied Biosystems). Expression of each ligand transcript was determined relative to the reference gene transcript (b-actin) and calculated as 2
. Data are presented as arbitrary units. The primers used to detect the transcripts were purchased from Integrated DNA Technologies and were as follows: IL-9R (forward, 5′-GGGTGACAAATCACCTCCAG-3′; reverse, 5′-GCCTCACTCTCCAAGGTCC-3′) and b-actin (forward, 5′-TCACCCACACTGTGCCCATCTACGA-3′; reverse, 5′-CAGCGGAACCGCTCATTGCCAATGG-3′).
Isolation and polyclonal activation of tissue-resident T cells Skin was obtained from healthy subjects undergoing cosmetic surgery procedures. Lung and small intestine samples were obtained from resection margins distant from the pathology of patients undergoing lung or gut surgery for various reasons. Tissue samples were extensively minced and then incubated for 2 hours at 37°C in RPMI 1640 containing 0.2% collagenase type I (Invitrogen) and deoxyribonuclease I (30 Kunitz units/ml) (Sigma-Aldrich). Thereafter, cells were collected by filtering the collagenase-treated tissue through a 40-mm cell strainer (Fisher Scientific). For experiments shown in fig. S3 , T cells were isolated from 3-week explant cultures maintained in IL-2 and IL-15 as previously described (38) . After being washed, tissue-derived T cells were then activated polyclonally using anti-CD3/anti-CD2/anti-CD28-coated beads, analogous to the activation of blood-derived T cells described above. Analysis of cytokine expression in T RM cells before and at different time points after polyclonal activation and experiments with neutralizing antibody to TGF-b were performed as described above for blood-derived T cells.
Isolation and activation of skin-resident ILCs
Cells isolated from healthy skin were plated at a density of 5 × 10 ) were examined for IL-9 production by flow cytometry.
Immunohistochemical staining
Patients with chronic plaque psoriasis (3 women and 10 men) with a median age of 54 years (SD ± 11 years) and patients with atopic dermatitis (3 women and 7 men) with a median age of 45 years (SD ± 20 years) were included. Diagnosis was based on typical clinical and histopathological criteria. The patients did not receive systemic or local therapy at the site where biopsy specimens were obtained for at least 3 weeks before the investigation. Punch biopsies (5 mm) were taken from lesional skin. Healthy skin was obtained from X healthy control subjects undergoing reconstructive surgery for aesthetical reasons. Skin samples were immediately embedded in optimal cutting temperature (OCT) compound, snap-frozen, and stored at −70°C until sectioning. Immunostaining was performed with the streptavidin-biotin complex/alkaline phosphatase method, as previously described (39) . Briefly, cryostat-cut tissue sections were air-dried, fixed for 10 min in 4% ice-cold acetone, and rehydrated in tris-buffered saline with 0.1% saponin. The sections were incubated with the primary antibody for 1 hour at room temperature, followed by a biotinylated secondary antibody and thereafter with streptavidin-biotin complex/alkaline phosphatase method (K0376; DakoCytomation). Finally, all sections were developed in new fuchsin-naphthol (KO624, DakoCytomation) and counterstained with hematoxylin. All skin sections were quantitatively analyzed with the digital image acquisition and analysis system NISElements Software BR 2.30 (Nikon) in an investigator-blinded fashion, as previously described (39, 40) .
Immunofluorescence double staining Double immunofluorescence was performed as previously described (39) . Briefly, tissue sections were serially incubated with the primary antibody (anti-IL-9) followed by incubation with Alexa Fluor 488-labeled goat anti-rabbit IgG for 1 hour each. Sections were then incubated with one of the following mouse anti-human antibodies for 1 hour: (i) anti-CD3, (ii) anti-CD4, and (iii) anti-CD8. Sections were then treated with Alexa Fluor 594-labeled goat anti-mouse IgG1 (Invitrogen). The specificity of the reaction was confirmed by omitting the primary or secondary antibodies as well as by using irrelevant isotype-matched antibodies as negative controls.
Statistical analyses
Primary methods of data analysis included descriptive statistics (means, medians, and SD). Differences between two sample groups were detected with the one-tailed Wilcoxon-Mann-Whitney test, a = 0.05. For comparisons of multiple groups, a Kruskal-Wallis one-way analysis of variance (ANOVA) with a Bonferroni-Dunn's post test for multiple means test was used, a = 0.05.
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